A unique blood-based diagnostic test for the earliest possible detection of cancer and genetic mutations.
Funding stage: Series A+
The investment teams managing our Octopus Ventures EIS products have made investments in some revolutionary early-stage EIS-qualifying companies, which are already changing the way we shop, live and work. Here’s a key example.
What is it?
Biofidelity’s mission is to provide access to precise cancer diagnostics for all patients. They’ve developed a unique blood-based diagnostic test for the earliest possible detection of cancer and genetic mutations, including melanoma, liver, kidney and breast cancer.
They can detect these DNA abnormalities, even when the concentration of the cancer or mutant DNA is too low to be picked up by existing diagnostic methods.
Why we like it
Biofidelity’s three-hour rapid test is low cost, has higher sensitivity than other tests and can be run on standard PCR machines, common in all hospitals. It could allow the earliest possible detection of cancer, up to 18 months earlier than methods currently used, and enable real-time monitoring post diagnosis. This should reduce the cost of treatment, improve patient outcomes and significantly help to reduce the burden on healthcare systems.
More companies we’ve backed
Ufonia uses artificial intelligence to develop automated clinical-grade conversations, capable of replacing routine medical appointments, and integrating into health systems.
An AI-driven technology solution to help optimise video quality whilst reducing bandwidth for streaming.
An online food delivery platform with a strong portfolio of brands, bringing the street food experience to your door.